Teen THC Vaping on the Rise: Solutions Beyond Government Regulations
Ryan Allway
November 9th, 2021
Exclusive, News, Top Story
Teen vaping of marijuana doubled between 2013 and 2020, according to a new study. In addition to harmful side effects, these trends are compounding problems that governments and businesses are already struggling with among the legal cannabis-consuming population. Fortunately, new technologies could be on the way to help detect and deter illegal use.
Let’s look at the growing teen vaping epidemic and how governments and how Cannabix Technologies Inc.’s (CSE: BLO) (OTC: BLOZF) technology could offer a solution.
Vaping on the Rise
According to a new study published in JAMA Pediatrics, teen vaping of marijuana doubled between 2013 and 2020, while the number of adolescents saying they vaped cannabis within the last 30 days rose 7-fold. The researchers see a shift in preference from dry herb to cannabis oil products that can contain much higher levels of THC.
Since marijuana is illegal at the federal level, many cannabis oil products are not subject to regulation. The CDC recently reported an outbreak of more than 2,800 lung injury cases, including 68 deaths, from e-cigarettes and vaping products between 2019 and 2020. Many of these products were THC cartridges containing Vitamin E acetate.
In addition to the harmful side effects, the growing cannabis usage by teens could impact future drivers and workers. For example, marijuana slows reaction time, impairs the judgment of time and distance, and decreases coordination, creating potentially dangerous situations behind the wheel or operating heavy machinery at a worksite.
Government Regulations
The FDA took some action on the matter by rejecting more than a million e-cigarette and related products in September, saying they appeal to underage teen users. While the move effectively took thousands of products off the market, the agency delayed its decision on most of the largest vaping companies, including Juul and a handful of others.
Last month, the agency authorized R.J. Reynolds Vuse as the first e-cigarette approved for marketing in the United States. The FDA said that the company submitted data showing that its products helped smokers quit or significantly reduce the use of their cigarettes. But, the agency noted that it rejected ten other requests for flavored products.
In addition to banning many e-cigarettes, the FDA strengthened its warnings to the public about using THC-containing vaping products and any products obtained off the street. And finally, it also continues to monitor samples sent in by state and local authorities to determine cannabinoid levels along with any harmful additives.
Investing in Solutions
Legalizing cannabis on a state level means that there will likely always be a market for THC-containing vape products, along with various other forms of cannabis. Like alcohol and other harmful drugs, enforcement may ultimately rely on detection and deterrence, particularly when driving or operating heavy machinery in a workplace environment.
The challenge is detecting cannabis consumption during peak impairment. While alcohol has a short half-life, THC remains present in urine for one month and hair follicles for up to three months. Breathalyzers that detect consumption within one to three hours of use are the ideal solution, and present a more fair and relevant drug screening method.
Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) is quickly developing cannabis breathalyzer technologies to address these challenges. In addition to securing patents on its unique approaches, its advanced prototypes are already in beta testing in real-world situations.
Looking Ahead
Teen marijuana vaping is a growing problem in the U.S., but regulations alone aren’t enough to solve the problem. With the Cannabix breathalyzer, police, workplaces, and schools could test for recent THC consumption and implement deterrence programs to stop teen usage before it grows into a bigger problem or harms their long-term health.
Investors may want to take a closer look at Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) given its leadership position in the cannabis breathalyzer space. With products already in beta testing, shareholders could see near-term catalysts upon commercialization and long-term growth potential as governments struggle to overcome these challenges.
For more information, visit the company’s website.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Plus Products, through its wholly-owned subsidiary, Carberry, operates as a branded cannabis products manufacturer with operations in California.
Xphyto Therapeutics Corp. was created to bridge the gap between traditional cannabis-based medicine and modern scientific approaches to therapeutic validation.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
